Compare abrdn Income Credit Strategies Fund (ACP) vs IDEXX Laboratories, Inc. (IDXX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
abrdn Income Credit Strategies Fund vs IDEXX Laboratories, Inc. — how do they compare? abrdn Income Credit Strategies Fund trades at $5.1 (market cap $641.16M), while IDEXX Laboratories, Inc. trades at $569.65 (market cap $46.22B). The key difference: IDEXX Laboratories, Inc. is far larger — about 72.1× abrdn Income Credit Strategies Fund's market cap, and abrdn Income Credit Strategies Fund pays a 18.2% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals.
| ACP | IDXX | |
|---|---|---|
Market Cap | $641.16M | $46.22B |
Sector | Financials | Health |
52-Week High | $5.98 | $766.68 |
52-Week Low | $5.01 | $526.44 |
Dividend Yield | 18.2% | — |
Enterprise Value | — | $47.12B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACP trades at $5.15 with a 1.38% daily gain, showing neutral technical signals with bearish moving averages. The stock maintains strong profitability with a 95.31% net income margin and attractive valuation at 7.74 P/E ratio. Recent dividend declarations of $0.08 per share demonstrate income focus, though revenue declined from $79M in 2024 to $42M in 2025 before projected recovery to $85M in 2026.
ACP presents a mixed outlook with sustainable dividends and undervalued metrics offset by revenue volatility and high leverage concerns. The 17% distribution rate faces sustainability questions with only 49% supported by net investment income. Investors should weigh the attractive yield against credit spread risks and global exposure in this high-beta closed-end fund.
IDEXX Laboratories (IDXX) trades at $570.58, down 4.23% over 24 hours, with a bullish technical signal and strong fundamentals. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $4.27 surpassing the $3.94 expectation. Revenue growth remains robust, supported by a 74.21% ROE and expanding diagnostic offerings. Recent news highlights product expansion, including a dual-species cardiac test, reinforcing its market leadership in veterinary diagnostics.
The outlook is positive, driven by durable competitive advantages and international growth potential. However, elevated valuation multiples and competitive pressures pose risks. Analyst consensus is bullish with a $683.33 price target, suggesting significant upside from current levels, though investors should monitor execution on guidance and macroeconomic headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About abrdn Income Credit Strategies Fund
abrdn Income Credit Strategies Fund is a diversified, closed-end investment management company. Its primary goal is to generate high current income, with capital appreciation as a secondary objective. The fund mainly invests in debt and loan instruments from issuers across various industries and regions.
Read more on ACP →About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →
